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Abstract
Background  Venous thromboembolism (VTE) confers considerable morbidity and mortality in
hospitalized patients, although few studies have focused on the critically ill population. The objective of
this study was to understand current approaches to the prevention and diagnosis of deep venous
thrombosis (DVT) and pulmonary embolism (PE) among patients in the intensive care unit (ICU).
Design Mailed self-administered survey of ICU Directors in Canadian university affiliated hospitals.
Results Of 29 ICU Directors approached, 29 (100%) participated, representing 44 ICUs and 681
ICU beds across Canada. VTE prophylaxis is primarily determined by individual ICU clinicians (20/29,
69.0%) or with a hematology consultation for challenging patients (9/29, 31.0%). Decisions are
usually made on a case-by-case basis (18/29, 62.1%) rather than by preprinted orders (5/29, 17.2%),
institutional policies (6/29, 20.7%) or formal practice guidelines (2/29, 6.9%). Unfractionated heparin
is the predominant VTE prophylactic strategy (29/29, 100.0%) whereas low molecular weight heparin
is used less often, primarily for trauma and orthopedic patients. Use of pneumatic compression devices
and thromboembolic stockings is variable. Systematic screening for DVT with lower limb ultrasound
once or twice weekly was reported by some ICU Directors (7/29, 24.1%) for specific populations.
Ultrasound is the most common diagnostic test for DVT; the reference standard of venography is rarely
used. Spiral computed tomography chest scans and ventilation–perfusion scans are used more often
than pulmonary angiograms for the diagnosis of PE. ICU Directors recommend further studies in the
critically ill population to determine the test properties and risk:benefit ratio of VTE investigations, and
the most cost-effective methods of prophylaxis in medical–surgical ICU patients.
Interpretation Unfractionated subcutaneous heparin is the predominant VTE prophylaxis strategy for
critically ill patients, although low molecular weight heparin is prescribed for trauma and orthopedic
patients. DVT is most often diagnosed by lower limb ultrasound; however, several different tests are
used to diagnose PE. Fundamental research in critically ill patients is needed to help make practice
evidence-based.
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Introduction
The most serious manifestation of DVT is PE, which occurs in
up to 1% of hospitalized patients and in 15% of patients at
postmortem [1]. Critically ill patients are at increased risk of
VTE due to their premorbid conditions, admitting diagnoses
such as sepsis and trauma, and events and exposures in the
ICU such as central venous catheterization, invasive tests and
procedures, and drugs that potentiate immobility [2,3]. While
autopsies have identified PE in 20–27% of ICU patients
[4,5], most clinical studies of VTE in the critically ill focus on
DVT. It is estimated that 90% of cases of PE originate in the
deep venous system of the lower limbs [6].
Two cross-sectional studies at the time of admission to the
ICU found a 10% prevalence of DVT diagnosed by lower limb
ultrasonography [7,8]. The risk of DVT developing during the
ICU stay was established in three longitudinal studies using
systematic screening [5,9,10]. Among ICU patients who did
not receive prophylaxis, 76% of whom were mechanically
ventilated, radioactive fibrinogen scanning for 3–6 days iden-
tified DVT in 3/34 (9%) patients [5]. Among 100 medical ICU
patients, 80% of whom were ventilated, Doppler ultrasound
twice weekly identified DVT in 10/18 (56%) patients who
received no prophylaxis, 17/43 (40%) who received unfrac-
tionated subcutaneous heparin, and 6/18 (33%) who
received pneumatic compression of the legs [9]. In a third
study of 102 medical–surgical ICU patients who had duplex
ultrasound during days 4–7 [10], DVT rates were 25, 19, and
7% in patients who received no prophylaxis, pneumatic com-
pression, and unfractionated heparin, respectively. Trauma
patients who do not receive prophylaxis, however, have DVT
rates of 60%, as demonstrated by serial impedance plethys-
mography and venography [11].
Two randomized trials have tested the efficacy of DVT pro-
phylaxis in medical–surgical ICU patients. In 1982, 119
patients were randomized to receive unfractionated heparin
(5000 U subcutaneously twice daily) or placebo [12]. Scan-
ning with I125 fibrinogen for 5 days identified DVT in 13 and
29% of these patients, respectively (relative risk, 0.45;
P < 0.05). More recently, 223 mechanically ventilated
patients with an exacerbation of chronic obstructive pul-
monary disease were randomized to 0.14 or 0.6 ml
nadroparin subcutaneously daily or placebo [13]. Duplex
compression ultrasound performed weekly identified DVT in
16% of the low molecular weight heparin group and 28% in
the control group (relative risk, 0.67; P < 0.05). There are,
however, no direct comparisons of low molecular weight
heparin versus unfractionated heparin in this population. This
is not the case for trauma patients; in one landmark trial,
Geerts et al identified DVT in 31% of patients randomized to
receive enoxaparin compared with 44% in patients receiving
unfractionated heparin (relative risk, 0.70; P < 0.05) [14].
The high risk of DVT and PE in critically ill patients, its potential
morbidity and mortality, and the need for accurate diagnosis
and effective prevention prompted a survey of Canadian ICU
Directors. The five specific goals were to understand deci-
sional responsibility for VTE prophylaxis, to understand the
type of prophylaxis prescribed, to understand approaches
used to screen for DVT, to understand approaches used to
diagnose DVT and PE, and to understand national interest in
a VTE research program in the ICU.
Methods
Instrument development
Items were generated for the instrument by examining original
research and position papers on VTE. To address the five
aforementioned objectives, items were clustered in five
domains: decisional responsibility for VTE prophylaxis (inten-
sivists, consultants, services, policies and guidelines), pro-
phylaxis utilization (unfractionated heparin, low molecular
weight heparin, pneumatic compression devices and thrombo-
embolic stockings), approach to DVT screening (frequency,
method, and patient subgroup), approach to VTE diagnosis
(laboratory and imaging studies), and recommendations for
further research on the prevention and diagnosis of VTE in
critically ill patients. Respondents were asked to report
current practice patterns in their ICU.
We used close-ended questions for the ICU demographic
data to maximize the accuracy and completeness of
responses [15]. Other responses were elicited using both
open and close-ended questions. Diagnostic test utilization
was recorded using five-point responses (1 = never used,
2 = rarely used, 3 = sometimes used, 4 = primarily used, and
5 = always used). The instrument was pretested prior to
administration for clarity of content and format.
Instrument administration
To select individuals with managerial responsibility and repre-
sentative clinical experience, we surveyed ICU Directors in
Canadian university affiliated hospitals running closed multi-
disciplinary units. We used a self-administered rather than an
interviewer-administered format to maximize the validity of
self-reported information [16]. We contacted nonrespon-
dents by facsimile with a second questionnaire [17], and then
a telephone call. The survey was conducted from October to
December 2000. Participation was voluntary and all
responses were confidential.
Analysis
We report means and standard deviations, and proportions as
appropriate. Chi square analysis was conducted to test for dif-
ferences in the diagnostic approaches to both DVT and PE.
Results
Of 29 ICU Directors approached, 29 (100%) participated.
Respondents represented 44 ICUs in Canada and 681 ICU
beds (Table 1). ICUs were primarily mixed medical–surgical
units (37/44, 84.1%) or exclusively surgical units (4/44,
9.1%), with a mean of 15.3 (9.9) beds per ICU.Critical Care    December 2001 Vol 5 No 6 Cook et al.
VTE prophylaxis for critically ill patients is primarily determined
by individual clinicians (20/29, 69.0%), with consultation from
a hematology or thrombosis service for challenging patients in
some centers (9/29, 31.0%). Decisions are made on a case-
by-case basis (18/29, 62.1%), infrequently prompted by
preprinted orders (5/29, 17.2%) or institutional policies (6/29,
20.7%), and rarely by a formal VTE prophylaxis practice guide-
line (2/29, 6.9%) (see www.critcare.lhsc.on.ca).
Unfractionated heparin (5000 U subcutaneously twice daily
or three times daily) is universally reported to be predominant
VTE prophylactic strategy (29/29, 100%). Low molecular
weight heparin is used in many centers for orthopedic surgery
patients (26/29, 89.7%), and in all ICUs that are regional
trauma centers (18, 100.0%).
Use of pneumatic compression devices and thromboembolic
stockings for VTE prophylaxis is presented in Table 2. Most
reasons for utilizing nonpharmacologic approaches related to
avoiding heparin exposure (e.g. current, recent or high risk of
bleeding and heparin-induced thrombocytopenia) rather than
to their perceived effectiveness at VTE prevention. Some ICU
Directors reported never using pneumatic compression
devices (11/29, 37.9%) or thromboembolic stockings (8/29,
27.6%). Combination VTE prophylaxis methods for postcar-
diac surgery patients (e.g. unfractionated heparin with pneu-
matic compression devices), and neurosurgery (e.g. low
molecular weight heparin with thromboembolic stockings)
were also described (data not shown). We did not elicit infor-
mation on the rationale for combination prophylaxis with phar-
macologic and nonpharmacologic approaches.
Early detection of DVT using surveillance screening was
reported in a minority of ICUs (7/29, 24.1%), for various pop-
ulations, including neurosurgery (n = 3), trauma (n = 3),
patients with prolonged immobility (n = 2), contraindications
to heparin (n = 2), or calf DVT (n = 1). The only systematic
screening method used is lower limb ultrasound once (n =2 )
or twice (n = 5) weekly.
The most common diagnostic test for DVT used in Canadian
ICUs is lower limb Doppler ultrasound, which is used signifi-
cantly more often than either D dimer or venography
(P < 0.0001) to detect DVT (Fig. 1). Doppler ultrasound is
reportedly used always (15/29, 51.7%) or primarily (14/29,
48.3%) for DVT diagnosis, whereas venography is rarely
(17/29, 58.6%) or never (4/29, 13.8%) used.
Figure 2 shows the tests used to diagnose PE. A spiral com-
puted tomography (CT) chest scan is used significantly more
often than any other test (P < 0.0001), reportedly used
always (5/29, 17.2%) or primarily (16/29, 55.2%). Ventila-
tion–perfusion scans are sometimes used (16/29, 55.2%),
whereas pulmonary angiograms are used sometimes (13/29,
44.8%) or rarely (11/29, 37.9%). A wide variation in D dimer
utilization is evident for diagnosing both DVT and PE in Cana-
dian ICUs.
ICU Directors uniformly endorsed the need for further studies
on VTE in critically ill patients. Topics to address included the
test properties and risk:benefit ratio of noninvasive VTE inves-
tigations in the ICU setting, accurate profiling of both the
thrombotic and bleeding risk among critically ill subgroups,
and the most cost-effective methods of VTE prophylaxis in
medical–surgical ICU patients.
Discussion
In this survey representing practice patterns in 44 Canadian
ICUs, we found that unfractionated subcutaneous heparin
was the dominant method for prophylaxis against VTE in
medical–surgical ICU patients, consistent with one random-
Table 1
Characteristics of participating intensive care units (ICUs)
Number of respondents 29
Number of hospitals represented (total) 36
Number of ICUs represented (total) 44
Number of beds per ICU (mean [SD]) 15.3 (9.9)
Number of beds (total) 681
Number of admissions per year (total) 35,735
Subgroups represented (n/44 ICUs [%])
Cardiovascular surgery 12 (27.3%)
Neurosurgery 20 (45.5%)
Trauma 18 (40.9%)
ICU length of stay (days) (mean [SD]) 4.9 (2.3)
Table 2
Use of pneumatic compression devices (PCD) and
thromboembolic stockings (TEDs) for venous
thromboembolism (VTE) prophylaxis in the intensive care unit
(ICU) as reported by 29 Canadian ICU Directors
PCD TEDs
All ICU patients 4 (12.5) 1 (3.1)
High risk of VTE (e.g. spinal cord injury) 7 (21.9) 1 (3.1)
Active bleeding 11 (34.4) 17 (53.1)
Recent bleeding 12 (37.5) 17 (53.1)
High risk of bleeding (e.g. coagulopathy) 7 (21.9) 17 (53.1)
Possible heparin-induced thrombocytopenia 5 (15.6) 8 (25.0)
Never 11 (34.4) 8 (25.0)
Data presented as n (%). Respondents may have endorsed more than
one reason for utilization.ized trial showing benefit in this setting [12]. As supported by
other randomized trials, low molecular weight heparin was
used for VTE prevention for trauma [14] and orthopedic
surgery [18] patients.
VTE prophylaxis with pneumatic compression devices and
thromboembolic stockings was variable, sometimes reported
in combination with pharmacologic prevention. For example,
thromboembolic stockings and low molecular weight heparin
were prescribed in some centers for neurosurgery patients,
as suggested by a recent trial showing that nadroparin and
thromboembolic stockings were more effective than stock-
ings alone for this population [19]. Pneumatic compression
devices were used in combination with unfractionated
heparin for cardiac surgery patients; this combination was
shown to be more effective than prophylaxis with heparin
alone for DVT prevention in another trial [20].
The reference standards of venography and pulmonary
angiography are seldom used in practice to diagnose DVT
and PE. The prevailing diagnostic approach for DVT is ultra-
sonography despite its unclear performance characteristics in
this population, instead of more accurate venography with its
attendant risks of patient transport and contrast dye-induced
renal insufficiency. A range of tests is used to diagnose PE:
D dimer, spiral CT scans, and ventilation–perfusion scans.
Difficulty in diagnosing PE is highlighted by the challenge of
an accurate pretest probability in the ICU setting, com-
pounded by uncertain properties of these tests in ventilated
patients who have acute and chronic illnesses and abnormal
chest radiographs. Respondents in the present survey
reported that helical CT chest scanning was the most
common diagnostic test for PE, perhaps partly because this
imaging procedure can concomitantly rule in or out other
diagnoses. Helical CT chest scans, however, have a sensitiv-
ity for PE ranging from 53 to 100% and a specificity ranging
from 81 to 100% according to a recent systematic review
[21].
D dimer tests are less useful diagnostically for VTE. Wells et
al found that the rapid whole blood assay for D dimer has a
sensitivity of 93% for proximal DVT, a sensitivity of 70% for
calf DVT, and a specificity of 77% compared with a reference
standard of impedance plethysmography [22]. Ginsberg et al
determined that the rapid whole blood assay for D dimer has
a sensitivity and a specificity for PE, as diagnosed by ventila-
tion–perfusion scan, of 85 and 68%, respectively [23]. Five
different quantitative latex agglutination tests for D dimer
yielded sensitivities of 97–100% and specificities of
19–29% when compared with pulmonary angiogram for the
diagnosis of PE [24]. Applying the foregoing test properties
of D dimer generated outside the ICU setting to critically ill
patients may be further compromised by activation of the
coagulation and inflammatory cascades in many critically ill
patients for myriad reasons [25,26].
We hypothesize that the modest amount of research on VTE
in the critically ill creates some uncertainty about best prac-
tice. The variation we identified in the present study with
respect to nonpharmacologic VTE prophylaxis and the diag-
nostic approach to PE may be related to insufficient studies
in critically ill patients. Additional factors explaining practice
variation may include different interpretations of the merits of
various tests and prophylactic methods, unique characteris-
Available online http://ccforum.com/content/5/6/336
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Figure 1
The use of bilateral lower limb ultrasound (US), D dimer, and
venography for the diagnosis of deep vein thrombosis, as reported by
Canadian Intensive Care Unit Directors.
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Figure 2
The use of D dimer, ventilation–perfusion scan (VQ), spiral chest
computed tomography (CT), and angiography (angio) for the diagnosis
of pulmonary embolism, as reported by Canadian Intensive Care Unit
Directors.
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D dimer VQ Chest CT Angiotics of each ICU population, and the influences of practice
setting such as test availability. When several high quality
studies generate consistent results and when there are few
barriers to implementation such as risk and cost, we found
that practice patterns regarding ventilator circuit and secre-
tion management were more standardized [27].
We used evidence from three randomized trials to conduct this
survey, suggesting that a self-administered format yields more
valid self-reports than interviewer-administered questionnaires
[16], that closed-ended formats yield more complete and valid
demographic data than open-ended formats [15], and that
appending second questionnaires to reminders maximizes
response rates [17]. Our response rate was high and our find-
ings generalizable to teaching institutions across Canada.
There are, however, several limitations to this study. First, ICU
Directors may not be aware of all local decisions, although their
responses are probably representative of care delivered in their
center. This limitation underscores the universal caveat of all
surveys, that stated practice may not reflect actual practice.
Second, using this sampling frame limits our ability to detect
individual clinician factors associated with practice patterns.
Third, this study was not designed to examine health services
factors associated with practice patterns such as ICU organi-
zational characteristics. Finally, we did not evaluate VTE treat-
ment strategies such as weight-based, nurse-managed heparin
nomograms, which can shorten the time to achieve therapeutic
anticoagulation compared with empiric dosing by physicians in
critical illness [28]. Nevertheless, survey methods yield useful
estimates of the prevalence and range of VTE prophylactic and
diagnostic strategies currently employed. In addition, the infor-
mation we obtained serves as a foundation on which to build
future research programs.
Research agendas in critical care are traditionally generated
through investigator-initiated projects, industry-initiated pro-
jects, or funding agency directives. An alternative approach to
set intensive care research priorities in the United Kingdom
and Ireland incorporated a survey, then nominal group tech-
niques to estimate consensus, and then a second survey to
validate the findings [29]. Of 37 research topics with the
strongest support, 24 addressed organizational aspects of
critical care and 13 involved clinical investigations or technol-
ogy assessment. In the present self-administered survey,
Canadian ICU Directors unanimously recommended the
development of collaborative research on VTE in the critically
ill. Raising the methodologic standards for diagnostic test
research [30], particularly in pulmonary medicine [31] and
VTE [32], could better inform clinical decisions and minimize
the dissemination of nondiscriminating and unnecessary
tests. Pressing investigations in this field include accurate risk
profiling for both VTE and bleeding events in critically ill sub-
groups, establishing likelihood ratios associated with clinical,
laboratory and radiographic diagnostic tests for VTE, and a
cost-effective comparison of unfractionated versus low mole-
cular weight heparin for medical–surgical ICU patients.
The 1986 National Institutes of Health Consensus Confer-
ence Report [33], the 1992 Thromboembolic Risk Factors
Consensus Group [34], the 1998 ACCP Consensus Com-
mittee on Pulmonary Embolism [35], the 1998 Antithrombotic
Consensus Conference [36], and the 1999 American
Thoracic Society Practice Guideline on the Diagnosis of
Venous Thromboembolism [37] do not mention medical–
surgical critically ill patients. Observational studies show that
VTE prophylaxis is prescribed in 33–86% of eligible patients
at risk [9,38–40], suggesting insufficient attention to VTE
prevention in the ICU. Recent editorials have proclaimed that
clinicians ‘must make their own decisions’ regarding heparin
prophylaxis for medical patients [41], and medical–surgical
ICUs have been called ‘the last frontier for prophylaxis’ [42].
The geographical boundaries of the ICU make this venue
highly suitable for conducting integrated research programs
[43]. Canadian intensivists appear interested in addressing
the many unanswered questions regarding VTE prevention
and diagnosis in critically ill patients.
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